Carl Icahn's Portfolio
|Ticker||# of Shares||Price||Value|
|View Additional Portfolio Information »|
Carl Icahn is a billionaire financier, ranking #18 on the 2007 Forbes 400 list with an estimated net worth of $14.5 billion.
Icahn built a name for himself in the 1980s as a corporate raider. After keeping quite for years, Icahn made a major comeback as a 'activist investor'. An activist investor agitates companies for changes, including buyouts, share buybacks, and dividend increases.
In 2007, Icahn's activism successfully pushed biotech company MedImmune into a sales agreement with AstraZeneca (NYSE: AZN). Icahn is also involved with biotech company Imclone Systems (Nasdaq: IMCL), where he is Chairman of the Board.
Icahn is also involved with developments at Biogen Idec (Nasdaq: BIIB) and WCI Communities (NYSE: WCI), which both unsuccessfully explored sales. WCI rejected a $22 per share takeover offer from Icahn in early 2007, only to see its stock plummet on the housing slowdown.
In 2008, Icahn targeted Yahoo! (Nasdaq: YHOO) after the Internet company failed to work out an acceptable merger agreement with Microsoft (Nasdaq: MSFT) Microsoft walked away from its bid for Yahoo! after months of bickering.
Top 10 News Items 2/13-2/17: Apple Breaks $500 Level; Greece Awaits Euro Leader Meeting on Bailout; Earnings Move Stocks Sharply
Top 10 News Items 8/15-8/19: HP Gets Slammed as Turnaround Hits a Major Snag; Eurobanks in Focus; Fears of 'Double-Dip Recession' Abound
Top 10 News Items 2/22-2/25: Crude Cracks the $100/Barrel Level; Latest Q4 GDP Reading Worse-Than-Expected at 2.8%; HP Tumbles on Earnings, Outlook